The Continuum of Pharmacist Prescriptive Authority
The Continuum of Pharmacist Prescriptive Authority
复制标题
DOI：
10.1177/1060028016653608
复制
发表时间：
2016-09-01
影响因子：
2.9
通讯作者：
Weaver, Krystalyn K.
中科院分区：
文献类型：
--
作者：
Adams, Alex J.;Weaver, Krystalyn K.
最近，药剂师对某些产品（如口服避孕药或纳洛酮）的处方权威不断增强。对于一些人来说，药剂师的处方权代表着药剂师在配药方面的传统角色的背离。然而，目前几乎所有州都以某种形式或方式赋予药剂师处方权。不同国家方法的多样性使得药剂师很难确定不同模型的优缺点。我们利用国家药房协会全国联盟 (NASPA) 提供的数据，该行业协会跟踪所有州的药房立法和法规，按照从最严格到最不严格的连续统一体来描述药剂师处方权模型。我们确定了当前药剂师处方权限的两个主要类别：(I) 协作处方和 (2) 自主处方。协作处方模型为治疗急性或慢性疾病提供了广泛的框架。当前的自主处方模型集中于不需要特定诊断的有限药物范围。药剂师处方权的方法并不相互排斥。我们预计未来几年将有更多的州采取限制较少的方法。
Recently momentum has been building behind pharmacist prescriptive authority for certain products such as oral contraceptives or naloxone. To some, prescriptive authority by pharmacists represents a departure from the traditional role of pharmacists in dispensing medications. Nearly all states, however, currently enable pharmacist prescriptive authority in some form or fashion. The variety of different state approaches makes it difficult for pharmacists to ascertain the pros and cons of different models. We leverage data available from the National Alliance of State Pharmacy Associations (NASPA), a trade association that tracks pharmacy legislation and regulations across all states, to characterize models of pharmacist prescriptive authority along a continuum from most restrictive to least restrictive. We identify 2 primary categories of current pharmacist prescriptive authority: (I) collaborative prescribing and (2) autonomous prescribing. Collaborative prescribing models provide a broad framework for the treatment of acute or chronic disease. Current autonomous prescribing models have focused on a limited range of medications for which a specific diagnosis is not needed. Approaches to pharmacist prescriptive authority are not mutually exclusive. We anticipate that more states will pursue the less-restrictive approaches in the years ahead.